IL6 and congenital rubella syndrome: CAR-NK therapy is less likely to cause cytokine release syndrome (CRS) due to lower levels of pro-inflammatory cytokines and absence of interleukin-6 (IL-6) expression, which is reported to be a hallmark of CRS.